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Abstract Quantitative and qualitative high-resolution (HR)
dependent and independent acquisition schemes on a
QqTOF MS (with resolving power 20,000–40,000) were
investigated for the analysis of pharmaceutical compounds
in biological fluids. High-resolution selected reaction mon-
itoring (HR-SRM) was found to be linear over three orders
of magnitude for quantitative analysis of paracetamol
in human plasma, offering a real alternative to triple quad-
rupole LC–SRM/MS. Metabolic stability of talinolol in
microsomes was characterized by use of three different
acquisition schemes: (i) information-dependent acquisition
(IDA) with a TOF MS experiment as survey scan and
product-ion scan as dependent scan; (ii) MSALL by collect-
ing TOF mass spectra with and without fragmentation by
alternating the collision energy of the collision cell between
a low (i.e., 10 eV) and high setting (i.e., 40 eV); and (iii) a
novel independent acquisition mode referred to as “sequen-
tial window acquisition of all theoretical fragment-ion spec-
tra” (SWATH) or “global precursor ions scan mode” (GPS)
in which sequential precursor ions windows (typically 20 u)
are used to collect the same spectrum precursor and frag-
ment ions using a collision energy range. SWATH or GPS
was found to be superior to IDA or MSALL in combination
with UHPLC for qualitative analysis but requires a rapidly
acquiring mass spectrometer. Finally, the GPS concept was
used for QUAL/QUAN analysis (i.e. integration of qualitative
and quantitative analysis) of bosentan and its metabolites in
urine over a concentration range from 5 to 2,500 ng mL−1.
Keywords Mass spectrometry . High resolution . Fast
chromatography .Metabolism . QUAL/QUAN
Introduction
In the drug-discovery process, the two major applications of
liquid chromatography coupled to tandem mass spectrome-
try (LC–MS–MS) are quantitative analysis of the parent
drug and identification of the metabolic biotransformation
products. Triple quadrupoles (QqQ), the instruments most
often used in the selected reaction monitoring mode for
sensitive, accurate, and precise quantification [1–3], also
enable qualitative analysis with information acquisition
schemes using full scan, precursor ion scan, selected reac-
tion monitoring, or neutral loss scan as survey experiments
and product ion scan as dependent experiments. Despite the
high selectivity of QqQ, the major drawback is the moderate
sensitivity for qualitative analysis. Therefore, in most cases,
the samples are analyzed twice: first on a QqQ for quanti-
fication and second on an ion trap (IT) or a quadrupole-time-
of-flight (QqTOF) for qualitative analysis. Integration
of qualitative analysis and quantitative analysis (QUAL/
QUAN) is, then, of great interest for drug discovery in
which sample throughput and/or sample volume is critical
and more high-quality data are needed to improve the drug-
selection process. These schemes have already been
explored on various mass spectrometers, including triple
quadrupoles, triple quadrupole linear ion traps, and
quadrupole-time-of-flight, but have not gained wide accep-
tance mostly because of performance limitations of the MS
instrumentation and workflow complexity [4–8]. With most
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atmospheric pressure ionization techniques, because of the
variable analyte response factor and matrix effects [9], ab-
solute quantification is mainly performed using reference
compounds and relative quantification remains possible to
follow the pharmacokinetic profile of metabolites.
Although for over two decades low-resolution instrumen-
tation was mostly used to find metabolites and elucidate their
structures, high-resolution (HR) mass spectrometry is becom-
ing increasingly essential for metabolite identification [10, 11].
In practice, two categories of mass spectrometer can achieve
high resolution (resolving power RP >30,000) with goodmass
accuracy (<5 ppm)—TOF-MS and Fourier transform (FT)-
MS, including the FT ion cyclotron resonance and the Orbi-
trap. The significant difference between the two types of
instrument is the duty cycle [12]. Liquid chromatography is
extremely important in analyte preconcentration and sample
cleanup, and in recent years significant progress in separation
efficiency in liquid chromatography has been realized with the
development of sub-2 μm particles or core-shell technology,
resulting in LC peak widths of only a few seconds, which
challenges the MS duty cycle [13]. High-resolution mass
spectrometry is an attractive alternative to quadrupole SRM
quantification because almost no tuning is required and large
numbers of analytes can be analyzed simultaneously. Howev-
er, similar sensitivity, precision and accuracy must be achieved
with these instruments. With resolving power RP higher than
20,000, selected ionmonitoring quantification started to attract
interest, and recent work has shown the potential of new
developments in mass spectrometric equipment for alternative
approaches to SRM for quantitative analysis [14].
This work explores alternative approaches including tar-
geted and not targeted MS and MS–MS approaches based on
high-resolution mass spectrometry with resolving power above
20,000 in combination with fast chromatography for QUAL/
QUAN analysis. The first part focuses on high-resolution se-
lected reaction monitoring quantification of paracetamol in
human plasma. The second part is dedicated to a novel acqui-
sition strategy for drug metabolism based on multiple precursor
ion windows, denoted sequential window acquisition of all
theoretical fragments (SWATH) or global precursor scan
(GPS), which is compared with commonly used information-
dependent acquisition (IDA) and MSALL acquisition schemes.
The last section is devoted, using analysis of bosentan and its
metabolites in urine as an example, to description of the bene-
fits and limitations of SWATH for QUAL/QUAN approaches.
Experimental
Chemicals and reagents
Methanol (MeOH) and acetonitrile (MeCN) were obtained
from VWR (Leuven, Belgium). Ammonium acetate, formic
acid (FA), and acetic acid were obtained from Merck
(Darmstadt, Germany). Acetaminophen, (paracetamol,
APAP) was obtained from Sigma (Buchs, Switzerland).
Acetaminophen-cysteine (APAP-CYS) trifluoroacetic acid
salt, acetaminophen-glucuronide (APAP-GLU) monosodium
salt, and the deuterated analogue of acetaminophen (APAP-
d4) were purchased from Toronto Research Chemicals
(Toronto, Canada). Bosentan, its metabolites (desmethylbo-
sentan (M1), hydroxybosentan (M2), and hydroxydesmethyl-
bosentan (M3), and their d4 analogs, were obtained from
Roche (Basel, Switzerland) and talinolol was kindly provided
by Arzneimittelwerk Dresden (Dresden, Germany). Clonaze-
pam was provided by Lipomed (Arlesheim, Switzerland) and
oxycodone by Cambridge Isotope Laboratories (Andover,
MA, USA). Rat liver microsomes (RLM) and human liver
microsomes (HLM) were obtained from BD Biosciences
(Allschwill, Switzerland).
Analysis of acetaminophen in human plasma
Sample preparation
Protein in 50-μL plasma samples was precipitated by addi-
tion of the ice-cold solvent mixture MeOH–EtOH (1:1v/v)
in the ratio 4:1. Calibration standards and ISTD, APAP-d4,
were added at this step (40 μL of solutions in water added in
total). Samples were then mixed on a Thermomixer (Vau-
daux-Eppendorf, Buchs, Switzerland) for 10 min at 15 °C
and 1,400 rpm. Subsequent centrifugation was performed at
4 °C and 14,000g for 12 min. The supernatant was then
removed and evaporated to dryness. Sample reconstitution
was performed in 100 μL 5 mmol L−1 ammonium acetate
buffer (pH 4.75), subsequently mixed for 10 min at 15 °C
and 1,400 rpm. Human plasma (citrate) was provided by the
University Hospital of Geneva.
LC–MS–MS analysis
HPLC was performed with an UltiMate 3000 micro-LC
(Dionex, Germering, Germany), configured in binary high-
pressure gradient mode and controlled by Chromeleon 6.70
software (Dionex). Mobile phase Awas 5 mmol L−1 ammo-
nium acetate buffer (pH 4.75) and mobile phase B was
MeOH. The starting composition of the mobile phase was
5% B; this was held for 0.5 min, then changed to 25% B in
4.5 min, then to 80% B in 3 min (hold for 2 min), then back
to 5% B in 0.1 min, and equilibrated for 9 min for the next
injection. The column oven and the flow rate were set at
30 °C and 1 mL min−1, respectively. Samples (10 μL) were
injected on to an ODS-AQ 4.6 mm I.D. × 150 mm, S-5 μm
particle, reversed-phase column (YMC Europe, Dinslaken,
Germany) with a 2.0 mm I.D. × 4.0 mm C18 guard column
(Phenomenex, Torrance, CA, USA). Mass spectrometric
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detection was performed with a quadrupole-TOF MS (Tri-
pleTOF 5600, AB Sciex, Concord, Canada) operated in
positive mode with a DuoSpray ion source in high-
sensitivity mode at a resolving power (full width at half
maximum, FWHM, at m/z 400) of approximately 20,000
in MS–MS and 30,000 in MS mode. The automated cali-
bration device system (CDS) was set to perform an external
calibration every three samples. The source conditions were:
temperature 700 °C, curtain gas (CUR) 25, GS1 and GS2 at
60 and 70 (laboratory frame), respectively, and ion-spray
voltage floating (ISVF) at 5.5 kV. Collision energies (CE)
were set to 20 eV for APAP and APAP-d4, 13 eV for APAP-
GLU, and 35 eV for APAP-CYS.
The acquisition method was composed of three different
periods:
& period 1 (0–5.55 min) a product ion scan (precursor m/z
328.1, mass range m/z 100–1000, accumulation time
250 ms) and a TOF-MS scan (mass range m/z 100–
1000, accumulation time 200 ms);
& period 2 (5.55–6.61 min) a product ion scan (precursor
m/z 271.1, mass range m/z 100–1000, accumulation time
250 ms) and a TOF-MS scan (mass range m/z 100–1000,
accumulation time 200 ms); and
& period 3 (6.61–8.0 min) a product-ion scan (precursor m/
z 152.1, mass range m/z 100–1000, accumulation time
250 ms) and product ion scan (precursor m/z 156.1, mass
range m/z 100–1000, accumulation time 250 ms).
The duty cycle time for each period was 500 ms. Quan-
tification was performed with MultiQuant 1.2 software (AB
Sciex). The integration algorithm was MQL with Gaussian
smooth width of two points using a linear regression model
with 1/x2 weighting. The extraction window for HR-SRM
mode was set at 0.025 u for the fragment ions: APAP-GLU
m/z 152.1, APAP-CYS m/z 140.0, APAP m/z 110.1, and
APAP-d4m/z 114.1.
Analysis of talinolol incubation in microsomes
For microsomal incubations of talinolol, all concentrations
given hereafter are final concentrations in the incubation
mixtures. Pre-incubation at 37 °C in a Thermomixer was
performed for 3 min after mixing of an appropriate volume
of phosphate buffer (100 μL minus the volume of the other
components), 1 mg mL−1 microsomes (RLM or HLM;
10 μL) and 1 μmol L−1 talinolol. NADPH (1.2 mmol L−1)
was then added and incubation was again performed at
37 °C before quenching after different times (0.25, 0.5,
0.75, 1, 2, 4, and 6 h) by adding 400 μL MeOH–EtOH
(1:1v/v) with ISTD (0.781 μg mL−1 oxycodone and clona-
zepam in the precipitation solvent). Subsequent centrifuga-
tion for 10 min at 4 °C and 12,000g was then performed and
the supernatant was removed and evaporated to dryness
under vacuum in a Univapo 150 ECH concentrator (Uni-
equip, Planneg, Germany). These fractions were kept dry
at −20 °C until LC–MS(–MS) analysis.
The human and rat microsomal incubations of talinolol
were analyzed on an UltiMate 3000 RSLC system from
Dionex (Germering, Germany) controlled by Chromeleon
6.70 software (Dionex) and hyphenated to a TripleTOF
5600 mass spectrometer (AB Sciex) operating at a resolving
power of approximately 40,000 (FWHM at m/z 400).
Automated external calibration was performed every three
samples. Mobile phase A was 0.1% formic acid (FA) in
water and mobile phase B was 0.1% FA in MeCN. The
flow rate was set at 600 μL min−1 The binary gradient was
linear from 10% to 60% in 5 min The LC column was a
Kinetex C18 (2.1 mm I.D. × 100 mm, 1.7 μm, Phenomenex)
and was thermostatted at 50 °C. The injection volume was
of 5 μL. Oxycodone and clonazepam were used as internal
standards.
Three data acquisition schemes were investigated:
1. Information-dependent acquisition mode (cycle time
350 ms): HR TOF as survey scan (accumulation time
100 ms) and HR MS–MS as dependent scan with a CE
range 20–50 eV (four MS–MS dependent experiments)
(accumulation time 50 ms);
2. MSALL (cycle time 350ms): HR TOF MS at low energy
(CE010 V) (accumulation time 150 ms) and HR TOF
MS at high energy (CE035 V) (accumulation time
150 ms);
3. Sequential window acquisition of all theoretical frag-
ment ions spectra (SWATH) (cycle time 375ms): 15 PIS
(Q1 20 u window) (accumulation time 25 ms each PIS,
CE range 20–50 eV).
For all experiments, the TOF mass range was m/z 50–
650. MS data acquisition was performed using Analyst TF
1.5.1 and data processing was performed using PeakView
1.1 software (AB Sciex).
LC-MS analysis of bosentan and its metabolites in urine
Urine was spiked with bosentan and its three metabolites
(M1–M3) to obtain calibration and QC samples containing
5, 10, 25, 50, 100, 250, 500, 1000, and 2500 ng mL−1). Urine
was spiked with the d4 analogues used as internal standards to
obtain a final concentration of 100 ng mL−1. Before analysis
the urine was diluted five times with water and 5 μL was
injected on to the LC system. The analytes were separated on a
Luna C18(2) (2.0 mm I.D. × 100 mm, 2.5 μm) LC column
(Phenomenex, Brechbühler, Switzerland) in gradient mode
using an UltiMate 3000 RSLC system from Dionex (Germer-
ing, Germany) controlled by Chromeleon 6.70 software. Mo-
bile phase A was 0.1% FA in H2O and mobile phase B was
0.1% FA inMeCN. The gradient started at 40% B and reached
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90% B in 4 min The flow rate was of 0.4 mL min−1 and the
column was thermostatted at 40 °C. MS analysis was per-
formed with a TripleTOF 5600 mass spectrometer in SWATH
acquisition modewith eight Q1windows of 20 u fromm/z 494
to m/z 638. There was an overlap of 2m/z between each Q1
window. The TOF mass range was m/z 50–1000. Seven
product ion experiments were further performed with Q1 set
at unit resolution for the precursor ions: 538.3 (M1), 542.3
(M1-d4), 552.3 (Bosentan), 556.3 (Bosentan-d4), 554.3 (M3),
568.3 (M2), and 572.3 (M2-d4). The TOFmass range wasm/z
50–650. The accumulation time was set for all experiments at
25 ms for a total cycle time of 375 ms. Nitrogen was used as
collision gas and the collision energy was ramped from 20 to
60 eV. Quantification was performed with MultiQuant 2.0
software (AB Sciex). The integration algorithm was MQL,
applying a standard Gaussian smoothing algorithm with a
half-width equal to 1 point and using Wagner regression fit.
The extraction windowwas set at 25 mDa for the bosentan, its
metabolites and the d4 internal standards.
Results and discussion
Quantification of acetaminophen in human plasma
by HR-SRM
Triple-quadrupole mass spectrometers have become the
instruments most widely used for quantitative LC–MS anal-
ysis in the selected reaction monitoring mode (SRM). The
objective of this work was to evaluate the quantitative
performance (i.e., precision, accuracy, and linearity) of the
QqTOF instrument (TripleTOF 5600) in MS–MS mode for
quantitative analysis of APAP in human plasma. The major
advantage of high resolution MS–MS on a QqTOF, also
referred as HR-SRM, compared with SRM is the limited
MS method development. Indeed with HR-SRM acquisi-
tion, the full-scan product-ion spectrum is recorded, and for
quantitative analysis there is no need to define the product
ion in advance; moreover, the MS–MS spectrum enables
compound structural characterization to be performed. The
analytes were isolated from the matrix by protein precipita-
tion and separated by an LC gradient before MS detection
using positive polarity electrospray. The method was found
to be linear over three orders of magnitudes (3.573 to
10,000 ng mL−1). Precision and accuracy for APAP quality
controls (QC) are listed in Table 1 and were better than 15%.
The dynamic range and limit of quantification were found to
be similar to those of a triple-quadrupole instrument (4000
QTRAP, AB Sciex; data not shown), demonstrating the
quantitative ability of the HR-SRM mode for APAP. Repre-
sentative chromatograms obtained from a blank plasma
sample and from a quality-control sample at the limit of
quantification are shown in Fig. 1a and b. The LC–HR-
SRM traces of two other monitored metabolites: APAP-
GLU, a phase II metabolite of APAP, and APAP-CYS, a
further metabolite of the APAP-glutathione metabolite, are
also presented in Fig. 1. The APAP-GLU trace of the blank
plasma shows an interfering ion at tr04.16 min, which is
Table 1 Precision and accuracy
for quantification of APAP in
human plasma (calibration and
QC samples)
Calibration
standards
Conc.
(ng mL−1)
Measured
concentration (ng mL−1)
Mean
(ng mL−1)
RSD (%) Accuracy (%)
Day 1 Day 2
Series 1 Series 2 Series 3
Cal 1 3.573 3.695 3.497 3.386 3.526 4.4 98.7
Cal 2 6.253 5.966 6.350 6.768 6.361 6.3 102
Cal 3 15.63 15.25 16.62 15.92 15.93 4.3 102
Cal 4 40.02 38.41 38.15 39.83 38.80 2.3 96.9
Cal 5 100.1 103.3 103.8 103.6 103.6 0.2 103
Cal 6 250.1 244.8 258.2 254.8 252.6 2.8 101
Cal 7 640.3 680.9 677.3 656.6 671.6 2.0 105
Cal 8 1601 1651 1586 1565 1601 2.8 100
Cal 9 4002 4131 3846 3828 3935 4.3 98.3
Cal 10 10010 9404 9108 9435 9316 1.9 93.1
QC
LLOQ 3.573 3.060 3.784 3.881 3.575 13 100
Low 6.253 5.918 6.711 6.005 6.211 7.0 99.3
Medium 250.1 244.2 253.9 265.9 254.7 4.3 102
High 10010 9174 9348 9075 9199 1.5 91.9
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well separated from APAP-GLU eluting at tr04.3 min and is
small enough to not affect quantitative performance. Inter-
estingly, the extracted ion current profile in TOF mode at RP
30,000 (i.e., high resolution selected ion monitoring, or HR-
SIM) does not show the interference (Fig. 1c). It is generally
accepted that MS–MS provides additional selectivity and
therefore better limits of quantification. However, one must
remember that isolation of the precursor ion is performed at
unit mass. In this case, several ions were observed in 1-u
precursor windows at m/z 328 in TOF mode, and one of
these generated isobaric fragment interference. To define
which acquisition mode between HR-SIM and HR-SRM is
optimum for quantification performance, and which RP is
required, remains a difficult task. Certainly a resolving power
of 10,000 is not sufficient and it is considered that an RP of
30,000 seems to be adequate for HR-SIM analysis [15]. How-
ever, HR-SRM gains from better signal-to-noise ratio and, in
general, several product ions are available for quantitative
analysis. Ultimately, which approach will be more efficient is
certainly analyte and limit of quantification-dependent and the
use of both approaches is highly recommended.
LC–MS analysis of talinolol incubations in liver
microsomes
Investigation of metabolic stability in microsomes is an
important step in early drug characterization. Degradation
of the parent drug can be measured on a triple-quadrupole
instrument by using the selected reaction monitoring mode,
and the metabolites can be detected by using subsequent
experiments, for example targeted product ion, neutral loss,
or precursor ion scan modes. However, triple-quadrupole
instruments suffer from limited sensitivity in these modes
and, generally, product-ion spectra are recorded on ion-trap
or triple-quadrupole linear ion-trap instruments. High-
resolution mass spectrometry offers unique possibilities for
quantification of the parent drug but also for identification
of metabolites. Quantification can be performed in HR-
selected-ion monitoring mode post-acquisition or in HR-
selected reaction monitoring mode, and metabolites can be
identified using either predictive metabolism [16] or mass
defect filtering [17].
Talinolol is a highly efficient and selective β1-adreno-
ceptor blocking agent. Oxidation at the cyclohexyl moiety
has been described as the major metabolic pathway gener-
ating several metabolites hydroxylated in different stereo-
chemical positions [18]. After incubation for 2 h of a
1 μmol L−1 solution talinolol in rat liver microsomes, six
hydroxylated metabolites could be identified (Fig. 2, M1–
M6) by use of mass-defect filtering. A mass defect filter is
based on the shift of the mass defect from the parent drug
(the non-integral value from the nominal value) to its metab-
olites. The filter (windows of 25 mDa for phase I metabo-
lites) retains m/z ions, defects of which are close to that of
the parent drug, and interfering ions are automatically re-
moved. Elemental formulas are generated with accurate
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Fig. 1 LC–MS traces of APAP, APAP-CYS, and APAP-GLU in
human plasma. (A) HR-SRM traces obtained from blank plasma. (B)
HR-SRM traces obtained from an APAP quality-control sample at the
LOQ (3.573 ng mL−1). (C) HR-SIM traces obtained from an APAP
quality-control sample at the LOQ (3.573 ng mL−1)
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Fig. 2 Extracted ion current profile for talinolol and its hydroxylated
metabolites from MS-TOF acquisition at a resolving power of 30,000
after incubation of talinolol with rat liver microsomes for 2 h
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mass and isotopic distribution fit. The decrease of the parent
drug and the increase of the metabolites during incubation
for 6 h could be quantified post-acquisition by use of HR-
SIM. Chromatographic resolving power is essential in drug
metabolism studies, particularly when many isobaric metab-
olites are generated. With our chromatographic arrangement
using 1.7-μm particle columns, the chromatographic peak
width was approximately 1–2 s. For quantitative analysis,
approximately 10–12 data points are required, meaning that
the total duty cycle of all experiments should not exceed
350 ms to maintain chromatographic performance. Whereas
HR full scan can be used to find and quantify metabolites,
generation of product-ion spectra remains essential for char-
acterization of structure. Typical metabolite identification is
based on information-dependent acquisition (IDA) in which
HR full scan serves as survey scan and four product ion
spectra are recorded as dependent scans by applying on-the-
fly selection criteria to the survey scan, for example mass
defect filtering. The product-ion spectrum of metabolite M4
is illustrated in Fig. 3a. Hydroxylation is a major metabolic
process and hydroxylation of talinolol can occur at the tert-
butyl, benzyl, or cyclohexyl moiety. Spectra interpretation is
often challenging and a variety of approaches can be con-
sidered, for example:
1. comparison with synthetic reference; or
2. use of prediction software based on fragmentation rules.
Accurate mass is particularly useful for interpretation of
MS–MS spectra because it enables calculation of elemental
formulae for the fragments and definition of whether they are
even or odd-electron ions [10]. In this instance we used a
bottom-up approach to perform spectral interpretation on the
basis of the structural constraints of the talinolol and the
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Fig. 3 Mass spectrum of
metabolite M4 at retention time
1.74 min. (A) Information-
independent acquisition mode
with a dependent product-ion
spectrum, Q1 at unit mass. (B)
MSALL, high-energy experi-
ment. (C) SWATH spectrum
with Q1 window m/z 374–394
Table 2 Experimental arrangement of talinolol LC–MS analysis after
two incubations in rat liver microsomes Information-dependent
acquisition
Q1 window m/z TOF range m/z CE (eV) Dwell time (ms)
1 Open 50–650 10 100
2 Unit 50–650 20–60 50
3 Unit 50–650 20–60 50
4 Unit 50–650 20–60 50
5 Unit 50–650 20–60 50
MSALL
Q1 window m/z TOF range m/z CE (eV) Dwell time (ms)
1 Open 50–650 10 150
2 Open 50–650 35 150
SWATH
Q1 window m/z TOF range m/z CE (eV) Dwell time (ms)
1 300–320 50–650 10–40 25
2 318–338 50–650 10–40 25
3 336–356 50–650 10–40 25
4 354–364 50–650 10–40 25
5 372–392 50–650 10–40 25
6 390–410 50–650 10–40 25
7 408–428 50–650 10–40 25
8 426–446 50–650 10–40 25
9 444–464 50–650 10–40 25
10 462–482 50–650 10–40 25
11 480–600 50–650 10–40 25
12 498–518 50–650 10–40 25
13 516–536 50–650 10–40 25
14 534–554 50–650 10–40 25
15 552–572 50–650 10–40 25
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measured fragments. PeakView software has a fragment pane
option that calculates all possible even or odd-electron frag-
ments by cutting existing bonds. For the fragments of metab-
olite M4, m/z 209 and 226 ions were found to be specific for
the unchanged benzyl moiety. At that stage, it could be pos-
tulated that hydroxylation occurred at the tert-butyl or cyclo-
hexyl moiety. In a second iteration, both possible structures
were submitted to the fragment pane routine and it was found
that fragments at m/z 324 and m/z 116 were specific for the
structure with the hydroxylation at the cyclohexyl moiety. M2
to M6 could be identified as talinolol hydroxylated at the
cyclohexyl moiety, and M1 was oxidized at the tert-butyl
moiety. The major advantage of the bottom-up approach
compared with the use of fragmentation rules is that the
software is issued to match the fragment ions with the struc-
tural and elemental composition constraints of the parent drug
in a first iteration and is independent of fragmentation rules
that are compound-dependent.
IDA is a powerful supervised MS(–MS) acquisition tech-
nique but has two main limitations:
1. some relevant precursor ions will not be selected for
performing collision-induced dissociation whatever se-
lection criteria are defined; and
2. quantification is challenging because no continuous da-
ta are collected during the complete LC peak elution.
In combination with liquid chromatography, unsupervised
MS and MS–MS spectra generation have been described and
are generally referred as MSE or MSALL. In such an arrange-
ment, data are collected on a high-resolution instrument typ-
ically of QqTOF geometry with the quadrupole operating in
wideband mode and collecting, alternately, mass spectra with
and without fragmentation by setting the collision energy of
the collision cell in low (i.e. 10 eV) and high mode (i.e.
40 eV). Because only two experiments are necessary, the
MS duty cycle is far less critical compared with IDA or
multiple product ion scan experiments. The background-
subtracted MSALL spectrum (high-energy) of metabolite M4
(talinolol incubation 2 h) is illustrated in Fig. 3b. Most of the
ions present in Fig. 3a are present in this spectrum. Compared
with the product-ion spectrum obtained by unit mass Q1
isolation, the MSALL experiment has no selection of the pre-
cursor ion and additional ions are observed at m/z 80 or m/z
428 which do not originate from the hydroxylated talinolol
precursor ion but arise from co-eluting interferences. Data
processing can be used to improve the quality of the spectra
but does not enable generation of high-quality spectra [19]
from low-intensity peaks, for example those of metabolites
M2 and M1. MSALL theoretically enables generation of MS–
MS data for any precursor ion but suffers from lack of selec-
tivity, because of the absence of precursor ion selection, and
therefore challenges data processing, in particular with dirty
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Fig. 4 Heat map of SWATH experiments (15 product-ion experi-
ments) of the LC–MS analysis after incubation of talinolol with rat
liver microsomes for 2 h. Blue (zero), red max signal corresponding to
10% of base peak
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Fig. 5 LC–MS analysis of
bosentan and its metabolites
spiked at 100 ng mL−1 in urine.
(A) Total ion chromatogram
obtained from 15 MS–MS
experiments (eight SWATH and
seven product-ion experi-
ments). (B) Extracted ion cur-
rent profile from SWATH
windows using a 0.025-u
window
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samples. On the other hand, on the LC time scale, using unit
Q1 window, a given mass range (i.e.m/z 50-650) would result
in 600 MS–MS experiments being performed.
An interesting approach to keep the benefits of the MSALL
approach and to reduce sample complexity is to use multiple
Q1 precursor ion windows at a given width (i.e. 25 u). This
independent acquisition method is referred as sequential win-
dow acquisition of all theoretical fragment ions spectra
(SWATH) and has been described for analysis of peptides
[20, 21]. It has also been used for qualitative analysis of low-
molecular-weight compounds, andwas called global precursor
ions scanmode (GPS) [22]. The talinolol sample incubated for
2 h with rat liver microsomes was analyzed using 15 product-
ion scan experiments (m/z 50–650) with Q1 set at an increas-
ing 20 u window (Table 2). To maintain a reasonable duty
cycle of 375 ms for UHPLC, the duty cycle for each experi-
ment was set to 25 ms on the QqTOF instrument. In contrast
with MSALL, for which two experiments are necessary, in
SWATHmode intact precursor and fragment ions are collected
in the same spectrum. This is achieved by using a collision
energy ramp in the collision cell (i.e. 10, to 45 eV) from low to
high. Each acquired Q1 isolation window can be processed
individually by applying a variety of filtering techniques, for
example isotope filter or mass defect filter. An elegant way to
visualize the data is to use heat-map representation as illustrat-
ed in Fig. 4. It can be clearly seen that metabolites M1–M6 are
measured in the same window (m/z 372–392) whereas talino-
lol is measured in a different one (m/z 354–374). In this
analysis, the mass range covered was 272 u, which is sufficient
to investigate phase I metabolites. The Q1 isolation window
was set to 20 u and centered on the m/z value of talinolol. To
cover phase I and II metabolites variable windows sizes should
be defined. In a SWATH experiment, all the relevant data are
collected in a single LC–MS analysis and the data can be
processed post-acquisition using any strategy. The product
ions spectrum of metabolite M4 is presented in Fig. 3c and,
compared with the MSALL experiment, no interferences are
observed around low mass fragments. In contrast with the
MSALL experiments, metabolites M1 andM2 could also clear-
ly be characterized from their product-ion spectra. As a matter
of fact, SWATH has several advantages over MSALL:
1. precursor and fragment ions in the same spectrum;
2. fewer precursor ion interferences; and
3. quantitative analysis can be performed on the precursor
ion or on any fragment ions.
QUAL/QUAN analysis of bosentan in urine by sequential
window acquisition of all theoretical fragment ions spectra
or global precursor ions scan
Bosentan (Tracleer) is an oral dual endothelin receptor
antagonist which is currently approved for treatment of
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Fig. 6 SWATH spectrum of
metabolite M3 from Fig. 5,
with Q1 window m/z 548–568
Table 3 Precision and accuracy for analysis of bosentan and its
desmethylhydroxy metabolite in urine, on the basis of quality-control
samples
ng mL−1 n01 n02 n03 Average RSD (%) Accuracy
(%)
Bosentan
QC01 5 4.42 4.40 4.93 4.58 6.6 91.6
QC02 10 10.6 10.8 10.2 10.6 2.9 105
QC06 250 252 306 296 285 10 114
QC08 1000 651 1182 1181 1005 31 101
Desmethylhydroxybosentan
QC01 5 4.29 4.19 3.53 4.00 10 80
QC02 10 8.80 7.21 7.78 7.90 10 79
QC06 250 301 259 232 265 14 106
QC08 1000 1080 897 1101 1026 11 103
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pulmonary arterial hypertension (PAH) [23]. Bosentan
forms three metabolites (Fig. 5): M1, desmethylbosentan,
M2, hydroxy bosentan, and M3, desmethylhydroxylbo-
sentan. Several LC–MS–MS methods have been devel-
oped to quantify bosentan and its metabolites in plasma
using the selected reaction monitoring mode [24] and the
fragmentation mechanism has been extensively investi-
gated [10, 25]. Bosentan was used as a model compound
to further investigate the potential and limitations of GPS
for QUAL/QUAN approaches. In this study the analytes
were analyzed from 5 to 2,500 ng mL−1, in urine, be-
cause urine resulted in a more complex endogenous
background (Fig. 5a) than plasma. With GPS analysis,
only one type of spectrum is generated, namely a
product-ion spectrum. By use of collision energy spread,
typically of 40 V, the precursor ions are still present in
the spectrum and also fragment ions can be recorded
over the complete mass range (Fig. 6) and can be used
for quantification. For bosentan and its metabolites, deu-
terium labeling (d4) of the internal standards is located
on the hydroxyethoxy side chain and the product-ion
spectra of the d0 and d4 analogs give exactly the same
fragments. Therefore, with a Q1 isolation window of 20
u it is not always possible to perform quantitative anal-
ysis in HR-SRM mode with isotopically labeled internal
standards. However, it is still possible to perform HR-
selected ion monitoring (HR-SIM) quantitative analysis
on the precursor’s ions, on the basis of their different m/
z. Precision and accuracy for quality-control samples of
bosentan and its desmethylhydroxyl metabolite over the
concentration range 5–2,500 ng mL−1 are summarized in
Table 3. Considering the accumulation time was only
25 ms, the results were found to be acceptable for
drug-discovery work. If the objective is to follow the
parent drug pharmacokinetics by use of HR-SRM mode,
one can also combine GPS experiments with classical
product-ion scans in which the Q1 isolation window is
1 u. As discussed previously, the major interest in
SWATH or GPS experiments is to collect all information
in a single LC–MS analysis, which is of great interest for
identification of biotransformation of the parent drug and
for absolute and relative quantification. Bosentan remains
one of the first examples of fragmentation at low energy
involving a radical fragmentation of an even-electron ion
at the sulfonamide bond [25]. Also, two different frag-
mentation mechanisms illustrated for the different metab-
olites involve loss of radical hydroxyl (.OH, m/z
280.0585) or neutral ammonia (NH3, m/z 280.030) both
of 16 u. A resolving power of 10,000 was not sufficient
to clearly differentiate both mechanisms and a RP of at
least 20,000 was necessary to distinguish these frag-
ments, as illustrated in Fig. 6. Because many pharma-
ceutical compounds are composed by C, H, N, O, or S,
an RP lower than 20,000 is considered to be critical for
MS and MS–MS spectra interpretation.
Conclusions
High-resolution mass spectrometry on a rapid acquisition
(<50 ms) QqTOF instrument with resolving power above
20,000 leads to new possibilities in QUAL/QUAN analysis.
First, it enables the analyst to benefit fully from the in-
creased separation performance of fast or ultra-high perfor-
mance liquid chromatography without compromising
chromatographic performance. Second, in quantitative anal-
ysis of acetaminophen in the HR-SRM mode, similar quan-
titative performance could be achieved as for quadrupole-
type instruments. For QUAL/QUAN drug-discovery work,
several dependent and independent MS strategies were con-
sidered including: targeted product ions scan, information-
dependent acquisition, MSALL, and the sequential window
acquisition of all theoretical fragment ions spectra concept.
Compared with MSALL, global precursor ions scan (GPS),
which is the low-molecular-weight version of SWATH,
resulted in significant performance improvement and
simplified data processing, because all the information
is collected in a single LC–MS run and precursor and
fragment ions are recorded within the same spectrum. Al-
though the potential of GPS has been demonstrated for drug
metabolism, it could also be applied in environmental, tox-
icology, doping, or food analysis, and in metabolomics
investigations.
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